Cover Image
Market Research Report

Global Asthma and COPD Drugs Market 2020-2026

Published by Orion Market Research Pvt Ltd Product code 949448
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Global Asthma and COPD Drugs Market 2020-2026
Published: May 21, 2020 Content info:
Description

Global Asthma and COPD Drugs Market Size, Share & Trends Analysis Report by Disease Type(Asthma and COPD), By Application (Cardiology, Orthopedics, General Surgery &Anesthesia, Neurology Urology, Others) and Forecast 2020-2026

The global asthma and COPD drugs market is estimated to grow significantly during the forecast period. The growth of the market is attributed to the increasing number of patients with asthma and COPD coupled with growing clinical trials on asthma and COPD drugs. Changing lifestyle of the people is a major cause of respiratory diseases among people. Trend of smoking, drinking alcohol and ill eating activity are increasing among the people which is a major risk for the development of various respiratory related diseases. As per COPD Foundation of the US, top three causes of COPD are environmental factor, smoking and genetic factor. COPD is mostly occurred in the people of age above 40 and having a history of smoking. About 90% of the COPD patients in the US have smoking history. Therefore lifestyle changes further increases the number of cases of respiratory diseases that further contribute in the market growth.

The global asthma and COPD drugs market is segmented on the basis of disease type and drug class. Based on the disease type, the market is further classified into asthma and COPD. The asthma segment is projected to have a considerable share in the global market owing to the high number of cases of asthma across the globe. Based on the drug class, the global asthma and COPD drugs market is further segmented into anti-inflammatory drugs, combination drugs, monoclonal antibodies, bronchodilators. Based on geography, the global asthma and COPD drugs market is further segregated into North America, Europe, Asia-Pacific and the Rest of the World. Among, region North America projected to have a considerable share in the global asthma and COPD drugs market.

The companies which are contributing to the growth of the global asthma and COPD drugs market include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Grifols, S.A., GlaxoSmithKline PLC, Pfizer Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.

Research Methodology

The market study of the global asthma and COPD drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for asthma and COPD drugs providers, end-user companies for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation

1. Global asthma and COPD drugs Market Research and Analysis by Disease Type

2. Global asthma and COPD drugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global asthma and COPD drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global asthma and COPD drugs market.
  • Insights about market determinants which are stimulating the global asthma and COPD drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Table of Contents
Product Code: OMR2021767

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Boehringer Ingelheim International GmbH
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Grifols, S.A.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. GlaxoSmithKline PLC
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Pfizer Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Asthma and COPD Drugs Market by Disease Type
    • 5.1.1. Asthma
    • 5.1.2. COPD
  • 5.2. Global Asthma and COPD Drugs Market by Drug class
    • 5.2.1. Anti-inflammatory Drugs
    • 5.2.2. Combination Drugs
    • 5.2.3. Monoclonal Antibodies
    • 5.2.4. Bronchodilators

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Amgen Inc.
  • 7.2. AptarGroup, Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Boehringer Ingelheim International GmbH
  • 7.5. Cipla Ltd.
  • 7.6. F. Hoffmann-La Roche Ltd.
  • 7.7. GlaxoSmithKline PLC
  • 7.8. Grifols, S.A.
  • 7.9. Glenmark Pharmaceuticals
  • 7.10. Merck & Co., Inc.
  • 7.11. MediciNova, Inc.
  • 7.12. Mylan N.V.
  • 7.13. Novartis AG
  • 7.14. Pfizer Inc.
  • 7.15. Respiratorius AB
  • 7.16. Teva Pharmaceutical Industries Ltd.
  • 7.17. Vectura Group plc
  • 7.18. Verona Pharma plc

LIST OF TABLES

  • 1. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL ASTHMA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL COPD DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

4. G

  • 5. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 6. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL COMBINATION DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 14. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 16. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY DISEASE TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
  • 3. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
Back to Top